Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach
Syed Ovais Aftab, Muhammad Zubair Ghouri, Muhammad Masood, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 183

Showing 1-25 of 183 citing articles:

Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12
Yun Teng, Fangyi Xu, Xiangcheng Zhang, et al.
Molecular Therapy (2021) Vol. 29, Iss. 8, pp. 2424-2440
Open Access | Times Cited: 163
A review on drug repurposing applicable to COVID-19
Serena Dotolo, Anna Marabotti, Angelo Facchiano, et al.
Briefings in Bioinformatics (2020) Vol. 22, Iss. 2, pp. 726-741
Open Access | Times Cited: 162
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
Ilaria Vicenti, Maurizio Zazzi, Francesco Saladini
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 4, pp. 325-337
Open Access | Times Cited: 112
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 82
Quantum computing led innovation for achieving a more sustainable Covid-19 healthcare industry
Shivam Gupta, Sachin Modgil, Priyanka C. Bhatt, et al.
Technovation (2022) Vol. 120, pp. 102544-102544
Closed Access | Times Cited: 71
A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19
Amit S. Lokhande, Padma V. Devarajan
European Journal of Pharmacology (2020) Vol. 891, pp. 173748-173748
Open Access | Times Cited: 102
Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach
Ziyad Tariq Muhseen, Alaa R. Hameed, Halah M. H. Al-Hasani, et al.
Journal of Molecular Liquids (2020) Vol. 320, pp. 114493-114493
Open Access | Times Cited: 96
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase
Jian‐Yuan Zhao, Saisai Guo, Dongrong Yi, et al.
Antiviral Research (2021) Vol. 190, pp. 105078-105078
Open Access | Times Cited: 82
In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2
Shridhar Hiremath, H. D. Vinay Kumar, M. Nandan, et al.
3 Biotech (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 69
Applications of density functional theory in COVID-19 drug modeling
Naike Ye, Zekai Yang, Yuchen Liu
Drug Discovery Today (2021) Vol. 27, Iss. 5, pp. 1411-1419
Open Access | Times Cited: 68
Potential molecular mechanisms of zinc- and copper-mediated antiviral activity on COVID-19
Isha Rani, Anmol Goyal, Mini Bhatnagar, et al.
Nutrition Research (2021) Vol. 92, pp. 109-128
Open Access | Times Cited: 65
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
Justin G. Julander, James F. Demarest, Ray Taylor, et al.
Antiviral Research (2021) Vol. 195, pp. 105180-105180
Open Access | Times Cited: 63
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11287-11368
Open Access | Times Cited: 58
Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19
Arpana Parihar, Zannatul Ferdous Sonia, Farjana Akter, et al.
Computers in Biology and Medicine (2022) Vol. 145, pp. 105468-105468
Open Access | Times Cited: 53
Role of Probiotics in the Management of COVID-19: A Computational Perspective
Quang Vo Nguyen, Li Chuin Chong, Yan-Yan Hor, et al.
Nutrients (2022) Vol. 14, Iss. 2, pp. 274-274
Open Access | Times Cited: 51
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
Anh‐Tien Ton, Mohit Pandey, Jason R. Smith, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 11, pp. 906-919
Open Access | Times Cited: 39
Global SNP analysis of 11,183 SARS‐CoV‐2 strains reveals high genetic diversity
Fangfeng Yuan, Liping Wang, Yīng Fāng, et al.
Transboundary and Emerging Diseases (2020) Vol. 68, Iss. 6, pp. 3288-3304
Open Access | Times Cited: 62
Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2
Manjesh Saakre, Deepu Mathew, V. Ravisankar
Beni-Suef University Journal of Basic and Applied Sciences (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 54
Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2
Titilayo Omolara Johnson, Abayomi Emmanuel Adegboyega, Opeyemi Iwaloye, et al.
Journal of Pharmacological Sciences (2021) Vol. 147, Iss. 1, pp. 62-71
Open Access | Times Cited: 49
Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations
Faez Iqbal Khan, Tongzhou Kang, Haider Ali, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 45
A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA‐dependent RNA polymerase of wild‐type and Delta subvariant AY.4 of SARS‐CoV‐2
İsmail Çeli̇k, Trina Ekawati Tallei
Journal of Cellular Biochemistry (2022) Vol. 123, Iss. 4, pp. 807-818
Open Access | Times Cited: 29
Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp)
Shabana Bibi, Mohammad Mehedi Hasan, Yuanbing Wang, et al.
Current Medicinal Chemistry (2021) Vol. 29, Iss. 1, pp. 152-162
Closed Access | Times Cited: 40
Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication
Rameez Hassan Pirzada, Muhammad Haseeb, Maria Batool, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1052-1052
Open Access | Times Cited: 33
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges
Xiao‐Ying Xu, Yuheng Chen, Xinyu Lu, et al.
Biochemical Pharmacology (2022) Vol. 205, pp. 115279-115279
Open Access | Times Cited: 24
Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation
Shahkaar Aziz, Muhammad Waqas, Tapan Kumar Mohanta, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 4, pp. 501-519
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top